Drug Profile

DF 003

Alternative Names: DF-003

Latest Information Update: 28 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Drug Farm
Class Anti-inflammatories; Cardiovascular therapies; Eye disorder therapies; Small molecules; Urologics
Mechanism of Action ALPK1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Retinal disorders
New Molecular Entity Yes

Highest Development Phases

Phase I Cardiovascular disorders; Retinal disorders
No development reported Renal failure

Most Recent Events

28 Sep 2026 No recent reports of development identified for phase-I development in Renal-failure(In volunteers) in USA (PO, Capsule)
26 Mar 2026 DF 003 receives Orphan Drug status for Retinal disorders in USA
05 Mar 2026 USFDA accepts rare disease evidence principles process (RDEP) for DF 003 for ROSAH syndrome

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com